ERVW-1 and neoplasm: Furthermore, addition of soluble recombinant ERVK-7 envelope glycoprotein inhibited on average 55% (−15% to 100%) of the ADCC mediated by plasma with HERV-K(HML-2) envelope-reactive antibodies, whereas the activity of plasma without HERV-K(HML-2) envelope-reactive antibodies, probably targeting alternative shared tumour antigens, was unaffected (Fig. 5e).